This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer’s disease: a study in a real life population


Van Puyvelde, Katrien, Mets, Tony


Geriatrics & Gerontology International, Volume: 11, No.: 3, Pages.: 256-261

Year of Publication



Aim: To record in real life the appreciation of elderly patients, their caregivers and physicians of a once daily formulation of prolonged release of galantamine in the treatment of mild to moderate Alzheimer’s disease.; Methods: A prospective, multicenter, observational study was conducted in 128 elderly patients, treated for 6 months with galantamine, donepezil or rivastigmine.; Results: Of the patients treated with galantamine, 82 of the 97 (84.5%) were continuing their treatment after 6 months. These patients reported their condition as improved in 49%, unchanged in 47% and worsened in 4%. Caregivers rated global evaluation as 37% better, 41% unchanged and 22% worse. Physicians rated global clinical impression of change as 46% better, 34% unchanged and 20% worse. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well (P<0.001). The incidence of serious side-effects possibly related to galantamine was 9.3%, which was not different from that in patients treated with other cholinesterase inhibitors.; Conclusion: In a real life setting, galantamine once daily is safe and is favorably appreciated by patients, their caregivers and physicians.; © 2011 Japan Geriatrics Society.

Bibtex Citation

@article{Van_Puyvelde_2011, doi = {10.1111/j.1447-0594.2010.00674.x}, url = {}, year = 2011, month = {jan}, publisher = {Wiley-Blackwell}, volume = {11}, number = {3}, pages = {256--261}, author = {Katrien Van Puyvelde and Tony Mets}, title = {Galantamine (Reminyl) once daily outcome and satisfaction survey ({RODOS}) in mild to moderate Alzheimer{textquotesingle}s disease: A study in a real life population}, journal = {Geriatrics {&} Gerontology International} }


administration & dosage, adverse effects, aged, alzheimer disease, and, caregivers, carer, cholinesterase inhibitors, cognition, drug therapy, female, galantamine, health, humans, indans, male, patient, patient satisfaction, phenylcarbamates, piperidines, psychology, reported, self, set, therapeutic use, treatment outcome, unspecified

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Cohort Study

Type of Outcomes

Behaviour, Cognition, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime